Adam Lewin’s practice focuses on resolving intellectual property disputes for technology and life sciences companies. He has experience litigating in federal district courts nationwide, the Courts of Appeals, and at the Patent Trial and Appeal Board.
Adam focuses on cost-effective, targeted strategies to resolve cases early or before litigation commences. One of his areas of expertise is in the development and execution of strategies involving patent eligible subject matter, a hotbed of recent activity in patent law. He has advised clients in the software, gaming, financial, and biotechnology industries on this topic and litigated extensively in this area before district courts and at the Federal Circuit. In addition to patent litigation, Adam advises clients on antitrust, copyright, trademark, and licensing matters, and he also has an active pro bono practice.
While attending law school Adam was Notes and Comments Editor of the Harvard Journal of Law and Technology and Technical Editor of the Harvard Environmental Law Review. He also interned with the San Francisco District Attorney’s Office. During his undergrad, Adam prepared a thesis based on original organic chemistry research involving self-assembling monolayers. His unique background gives him a facility with science and technology, along with an understanding of business goals and practicalities.
- Federal Circuit clarifies the “on-sale bar” (with Ewa Davison), Daily Journal, July 18, 2016
- Biotech companies turn to International Trade Commission (with Ewa Davison and Bryan Kohm), Daily Journal, April 14, 2016
- To Join or Not to Join: The Question of Membership in a Standard-Setting Organization (with Charlene Morrow and Tammi Hill), The Licensing Journal, Volume 35, Number 5, May 2015
- Medical Device Innovation in America: Tensions Between Food and Drug Law and Patent Law, Harvard Journal of Law & Technology, Volume 26, Number 1, Fall 2012